Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 4/20 | 0.40 |
| ▸ | ATP4B | P51164 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PKLR | P30613 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10922950 | 0.75 | ATP4A (0.46) | ATP4AATP4BGAATP53MAPT | |
| SCHEMBL2193489 | 0.73 | ATP4A (0.47) | ATP4AATP4BGAATP53MAPT | |
| SCHEMBL2193255 | 0.67 | ATP4A (0.72) | ATP4AATP4B | |
| SCHEMBL11062972 | 0.65 | ATP4A (0.52) | ATP4AATP4BGAATP53MAPT | |
| SCHEMBL6351485 | 0.64 | CYP3A4 (0.51) | ATP4AATP4B | |
| SCHEMBL10532145 | 0.64 | ATP4A (0.61) | ATP4AATP4BGAAKDM4ENPC1 | |
| SCHEMBL11105781 | 0.64 | NPC1 (0.37) | GAASMN1; SMN2KDM4ENPC1ALDH1A1 | |
| SCHEMBL31669621 | 0.64 | ATP4A (0.54) | ATP4AATP4BGAAKDM4ENPC1 | |
| SCHEMBL11001216 | 0.61 | ATP4A (0.47) | ATP4AATP4B | |
| SCHEMBL11004276 | 0.60 | ATP4A (0.41) | ATP4AATP4BALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150086497-A1 | Skin Lightening Compositions | ELC MAN LLC (US) | 2015-03-26 | — | — | US | claimed |
| EP-2521531-B1 | SKIN LIGHTENING COMPOSITIONS | ELC MAN LLC (US) | 2017-07-12 | — | — | EP | disclosed |
| US-20170035672-A1 | SKIN LIGHTENING COMPOSITIONS | ELC MAN LLC (US) | 2017-02-09 | — | — | US | disclosed |
| EP-3103437-A1 | SKIN LIGHTENING COMPOSITIONS | ELC Management LLC (US) | 2016-12-14 | — | — | EP | disclosed |
| US-9314415-B2 | Skin lightening compositions | ELC MANAGEMENT LLC (US) | 2016-04-19 | — | — | US | disclosed |
| US-8992897-B2 | Skin lightening compositions | ELC MANAGEMENT LLC (US) | 2015-03-31 | — | — | US | disclosed |
| US-20150086497-A1 | Skin Lightening Compositions | ELC MAN LLC (US) | 2015-03-26 | — | — | US | disclosed |
| US-20140212365-A9 | SKIN LIGHTENING COMPOSITIONS | NIKI YOKO (JP) | 2014-07-31 | — | — | US | disclosed |
| US-20140154190-A1 | Skin Lightening Compositions | ELC MANAGEMENT, LLC (US) | 2014-06-05 | — | — | US | disclosed |
| US-8722026-B2 | Skin lightening compositions | ELC MANAGEMENT, LLC (US) | 2014-05-13 | — | — | US | disclosed |
| US-20140112877-A1 | SKIN LIGHTENING COMPOSITIONS | NIKI YOKO (JP) | 2014-04-24 | — | — | US | disclosed |
| EP-2521531-A2 | SKIN LIGHTENING COMPOSITIONS | ELC Management LLC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20110171149-A1 | Skin Lightening Compositions | ELC MANAGEMENT LLC | 2011-07-14 | — | — | US | disclosed |
| WO-2011085015-A2 | SKIN LIGHTENING COMPOSITIONS | ELC MANAGEMENT LLC (US) | 2011-07-14 | — | — | WO | disclosed |
| US-4450164-A | ANTIULCER AND ANTISECRETORY AGENTS | SCHERING CORPORATION (US) | 1984-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171149-A1 | Skin Lightening Compositions | CUTA, TYR, DSG1 | ATP4A 3312/4885ATP4B 3659/4885GAA 2017/4885 |
| US-20140212365-A9 | SKIN LIGHTENING COMPOSITIONS | CUTA, TYR, DSG1 | ATP4A 3312/4885ATP4B 3659/4885GAA 2017/4885 |
| US-20170035672-A1 | SKIN LIGHTENING COMPOSITIONS | CUTA, TYR, DSG1 | ATP4A 3312/4885ATP4B 3659/4885GAA 2017/4885 |
| US-20140154190-A1 | Skin Lightening Compositions | TYR, MC1R, AHR | ATP4A 3964/4885ATP4B 4059/4885GAA 4754/4885 |
| US-20140112877-A1 | SKIN LIGHTENING COMPOSITIONS | CUTA, TYR, DSG1 | ATP4A 3312/4885ATP4B 3659/4885GAA 2017/4885 |
| US-20150086497-A1 | Skin Lightening Compositions | CUTA, TYR, DSG1 | ATP4A 3312/4885ATP4B 3659/4885GAA 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.